Efficacy and tolerability of meloxicam versus piroxicam in patients with osteoarthritis of the hip or knee. A six-month double-blind study

Clinical Drug Investigation

Volumn 13, Issue 4, 1997, Pages 175-184

  Hosie, J ^a   Distel, M ^b   Bluhmki, E ^c  

^a Great Western Medical   (United Kingdom)

^b Boehringer Ingelheim   (Argentina)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COXITIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; JOINT STIFFNESS; KNEE OSTEOARTHRITIS; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PAIN; PALLIATIVE THERAPY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; URINARY TRACT DISEASE;

EID: 0030899926     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199713040-00001     Document Type: Article

References (33)

1. Larkai E, Smith JL, Lidsky MD, et al. Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol 1989; 11 (2): 158-62
2. Coles LS, Fries JF, Kraines RG, et al. From experiment to experience: side effects of nonsteroidal anti-inflammatory drugs. Am J Med 1983; 74: 820-8
3. Fries JF, Williams CA, Bloch DA, et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991; 91: 213-22
4. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs - differences and similarities. N Engl J Med 1991; 324 (24): 1716-25
5. Fries JF, Miller SR, Spitz PW, et al. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology 1989; 96: 647-55
6. Kirchner JT. Nonsteroidal anti-inflammatory drug use in the elderly. Issues of compliance and safety. JAMA 1994; 94 (4): 300-4
7. Lund B, Distel M, Bluhmki E. A double-blind placebo controlled study of the different doses of meloxicam in patients with osteoarthritis (OA) of the knee [abstract 117]. 25th Scandinavian Congress of Rheumatology, Lillehammer, Norway, 1-4 June 1994. Scand J Rheumatol 1994; Suppl. 98
8. Engelhardt G, Homma D, Schlegel K, et al. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995; 44: 423-33
9. Engelhardt G, Bögel R, Schnitzler Chr, et al. Meloxicam: influence on arachidonic acid metabolism. Part I. In vitro findings. Biochem Pharmacol 1996; 51: 21-8
10. Pairet M, Engelhardt G. Differential inhibition of COX-1 and COX-2 in vitro and pharmacological profile in vivo of NSAIDs. In: Vane J, Botting J, Botting R, editors. Improved non-steroidal anti-inflammatory drugs. London, UK: Kluwer Academic Publishers, 1996: 103-19
11. Churchill L, Graham AG, Shih C-K, et al. Selective inhibition of human cyclo-oxygenase-2 by meloxicam. Inflammopharmacology 1996; 4: 125-35
12. Türck D, Roth W, Busch U. A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol 1996; 35 (1 Suppl.): 13-6
13. Lauffen H, Leitpolt M. The effect of activated charcoal on the bioavailability of piroxicam in man. Int J Clin Pharmacol Ther Toxicol 1986; 24 (1): 48-52
14. Nilsen OG. Clinical pharmacokinetics of tenoxicam. Clin Pharmacokinet 1994; 26 (1): 16-43
15. Martini C, Hunt S. The Nottingham Health Profile. In: S. McDowell, C. Newell, editors. Measuring Health: Oxford University Press, 1981
16. Karch FE, Lasagna L. Adverse drug reactions. JAMA 1975; 234: 1236-41
17. Giercksky KE, Huseby G, Rugstad HE. Epidemiology of NSAID-related gastrointestinal side effects. Scand J Gastroenterol Suppl. 1989; 163: 3-8
18. Linden B, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15mg with piroxicam 20mg in patients with osteoarthritis of the hip. Br J Rheumatol 1996; 35 Suppl. 1: 35-8
19. Biogden RN, Heel RC, Speight TM, et al. Piroxicam: a reappraisal of its pharmacology and therapeutic efficacy. Drugs 1984; 28: 292-323
20. Moser U, Waldburger H, Schwarz HA, et al. A double-blind randomised multicentre study with tenoxicam, piroxicam and diclofenac sodium retard in the treatment of ambulant patients with osteoarthritis and extra-articular rheumatism. Scand J Rheumatol 1989; Suppl. 80: 71-80
21. Paulsen GA, Baigun S, de Figuciredo JG, et al. Efficacy and tolerability comparison of etodolac and piroxicam in the treatment of patients with osteoarthritis of the knee. Curr Med Res Opin 1991; 12 (6): 401-12
22. Lewis T, Lain D, Baumgartner SW. Comparison of diflunisal and piroxicam in the management of patients with osteoarthritis. Clin Ther 19886; 9 Suppl. C: 15-26
23. Huskisson EC, Greenwood A. Naproxen and piroxicam. A comparative trial in rheumatoid arthritis. Eur J Rheumatol Inflamm 1983; 6: 242-6
24. Husby G, Holme I, Rugstad HE, et al. A double-blind multicentre trial of piroxicam and naproxen in osteoarthritis. Clin Rheumatol 1986; 5 (1): 84-91
25. Al Nahdi M. Efficacy and tolerability of long-term tenoxicam versus piroxicam in patients with rheumatoid arthritis or osteoarthritis. Curr Ther Res Clin Exp 1992; 52 (4): 639-45
26. Waterworth RF, Waterworth SM, Taylor KM. A comparison of tenoxicam and piroxicam in a long-term clinical study in patients with osteoarthritis of hip or knee joints. Eur J Rheumatol Inflamm 1985; 8 (1): 21-7
27. Lund B, Andersen RB, Fossgreen J, et al. A long-term randomised trial on tenoxicam and piroxicam in osteoarthritis of the hip or knee: a 24-month interim report focusing on the 12-24 month interval. Eur J Rheumatol Inflamm 1987; 9 (1-2): 58-67
28. Hunt SM, McKenna SP, Williams J. Reliability of a population survey tool for measuring perceived health problems: a study of patients with osteoarthrosis. J Epidemiol Community Health 1981; 35: 297-300
29. Hunt SM, McEwen J, McKenna SP, et al. Subjective health of patients with peripheral vascular disease. Practitioner 1982; 226: 133-6
30. Engelhardt G, Bögel R, Schnitzler CHR, et al. Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings. Biochem Pharmacol 1996; 51: 29-38
31. Vane J. Towards a better aspirin. Nature 1994; 367: 215-6
32. Distel M, Mueller C, Bluhmki E. Global analysis of gastrointestinal safety of a new NSAID, meloxicam. Inflammopharmacology 1996; 4: 71-81
33. Kirchner JT. Nonsteroidal anti-inflammatory drug use in the elderly: issues of compliance and safety. J Am Ostoepath Assoc 1994; 94 (4): 300-4